Cargando…

Infliximab in inflammatory bowel disease

Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD. Data from randomized controlled trials, large obser...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papamichael, Konstantinos, Lin, Steve, Moore, Matthew, Papaioannou, Garyfallia, Sattler, Lindsey, Cheifetz, Adam S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435871/ https://www.ncbi.nlm.nih.gov/pubmed/30937157 http://dx.doi.org/10.1177/2040622319838443

Ejemplares similares

Drug Clearance in Patients with Inflammatory Bowel Disease Treated with Biologics
por: Deyhim, Tina, et al.
Publicado: (2023)

A primer on common supplements and dietary measures used by patients with inflammatory bowel disease
por: Minhas, Hadi J, et al.
Publicado: (2023)

Defining and predicting deep remission in patients with perianal fistulizing Crohn’s disease on anti-tumor necrosis factor therapy
por: Papamichael, Konstantinos, et al.
Publicado: (2017)

Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease
por: Roblin, Xavier, et al.
Publicado: (2023)

Inflammatory bowel disease of the lung: The role of infliximab?()
por: Hayek, Adam J., et al.
Publicado: (2015)

Clinical Impact of Corrections to Infliximab and Adalimumab Monitoring Results with the Homogeneous Mobility Shift Assay
por: Papamichael, Konstantinos, et al.
Publicado: (2020)

Management of inflammatory bowel disease in poor responders to infliximab
por: Guerra, Iván, et al.
Publicado: (2014)

Biologic Concentration Testing in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2015)

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease
por: Vaughn, Byron P., et al.
Publicado: (2020)

Challenges in Therapeutic Drug Monitoring: Optimizing Biological Treatments in Patients With Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases
por: Papamichael, Konstantinos, et al.
Publicado: (2023)

Does infliximab increase complications after surgery for inflammatory bowel disease?
por: Holubar, Stefan D, et al.
Publicado: (2009)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
por: Papamichael, Konstantinos, et al.
Publicado: (2022)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Clinical Use and Mechanisms of Infliximab Treatment on Inflammatory Bowel Disease: A Recent Update
por: Guo, Yuan, et al.
Publicado: (2013)

Infliximab-Associated Acneiform Eruption in a Patient With Inflammatory Bowel Disease
por: Khatana, Usman Feroze, et al.
Publicado: (2021)

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease
por: Curci, Debora, et al.
Publicado: (2021)

Outcome of Immediate Dose Optimization of Infliximab in Inflammatory Bowel Disease Patients
por: Bacsur, Péter, et al.
Publicado: (2021)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Retrospective Cohort Study Comparing Infliximab-dyyb and Infliximab in Biologic-Naive Patients With Inflammatory Bowel Disease in the United States
por: Smith, Joshua T, et al.
Publicado: (2021)

Has the time been reached for pseudopolyps to be re-enrolled in endoscopic inflammatory bowel disease scores?
por: Politis, Dimitrios S, et al.
Publicado: (2019)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Barriers to Mesalamine Adherence in Patients with Inflammatory Bowel Disease: A Qualitative Analysis
por: Devlen, Jennifer, et al.
Publicado: (2014)

Tenascin-C Is Increased in Inflammatory Bowel Disease and Is Associated with response to Infliximab Therapy
por: Ning, Longui, et al.
Publicado: (2019)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Predictive factors of response to infliximab therapy in Brazilian inflammatory bowel disease patients
por: Martins, Camilla de Almeida, et al.
Publicado: (2023)

Switching from Infliximab to Biosimilar in Inflammatory Bowel Disease: A Review of Existing Literature and Best Practices
por: Bhat, Shubha, et al.
Publicado: (2021)

Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease
por: Guerra Veloz, María Fernanda, et al.
Publicado: (2018)

Clinical role, optimal timing and frequency of serum infliximab and anti-infliximab antibody level measurements in patients with inflammatory bowel disease
por: Bor, Renáta, et al.
Publicado: (2017)

Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis
por: Feuerstein, Joseph D., et al.
Publicado: (2016)

Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy
por: Parra, Rogério S., et al.
Publicado: (2018)

Policy Options for Infliximab Biosimilars in Inflammatory Bowel Disease Given Emerging Evidence for Switching
por: Husereau, Don, et al.
Publicado: (2018)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
por: Rolandsdotter, Helena, et al.
Publicado: (2017)

Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease
por: Hellmann, Jennifer, et al.
Publicado: (2021)

Therapeutic Drug Monitoring and Outcome of Infliximab Therapy in Pediatric Onset Inflammatory Bowel Disease
por: Kolho, Kaija-Leena
Publicado: (2021)

Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment
por: Bouhnik, Yoram, et al.
Publicado: (2022)

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
por: Van Stappen, Thomas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rg6ptd936urfpn3cggohq1c9dv